Better Long-Term Buy: AbbVie or Novo Nordisk?
Pharmaceutical companies Novo Nordisk (NYSE: NVO) and (NYSE: ABBV) seem to be headed in separate directions.
Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and obesity therapy Wegovy, is predicting sales to grow between 24% to 30% and operating profit to rise 28% to 34% this year.
AbbVie, on the other hand, thanks to the loss of patent protection for immunology blockbuster Humira, has forecasted 2023 adjusted earnings per share (EPS) to drop by 20% to 23%, from 2022 levels. Both stocks rewarded investors over the past decade, but for the long term, which is a better buy right now? Let's find out.
Source Fool.com
AbbVie Inc. Aktie
174,48 €
0,65 %
Die AbbVie Inc. Aktie genießt uneingeschränkte Beliebtheit: Nur Buy-Einschätzungen.
Ein Kursziel von 180 € für AbbVie Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 174.48 €.
